Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 2,000 Shares of Stock

Key Points

• CFO Oluyemi Okupe sold 2,000 Hims & Hers shares at an average price of $29.70, generating $59,400. The sale occurred under a pre-arranged Rule 10b5-1 plan and left him with 234,527 shares.
• HIMS shares fell 1.2% to $28.96, while the company’s latest quarterly results missed earnings expectations despite revenue rising 38.2% year over year to $753.2 million.
• Analysts maintain a consensus “Hold” rating with an average price target of $32.43; institutional investors own 63.52% of the company, while ongoing FTC-related litigation and regulatory concerns continue to pressure investor sentiment.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $29.70, for a total transaction of $59,400.00. Following the sale, the chief financial officer directly owned 234,527 shares in the company, valued at $6,965,451.90. This trade represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, September 22nd, Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.95, for a total value of $876,846.15.
• On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.82, for a total value of $354,860.66.
• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total value of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87.

Hims & Hers Health Trading Down 1.2%

NYSE:HIMS traded down $0.34 during mid-day trading on Friday, hitting $28.96. 10,052,970 shares of the company's stock were exchanged, compared to its average volume of 23,671,156. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The firm has a market capitalization of $6.76 billion, a P/E ratio of -45.97 and a beta of 2.44. The company has a 50 day simple moving average of $29.27 and a 200-day simple moving average of $28.24.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company's revenue was up 38.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. As a group, research analysts expect that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company's stock worth $183,485,000 after purchasing an additional 608,950 shares during the period. Bank of America Corp DE raised its holdings in shares of Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the period. Norges Bank bought a new position in shares of Hims & Hers Health during the 4th quarter worth about $62,153,000. Clear Street Group Inc. boosted its position in shares of Hims & Hers Health by 23.6% during the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company's stock worth $61,832,000 after purchasing an additional 363,893 shares in the last quarter. Finally, State of Michigan Retirement System grew its stake in shares of Hims & Hers Health by 13.7% in the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company's stock valued at $48,549,000 after buying an additional 280,900 shares during the period. Institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. JPMorgan Chase & Co. assumed coverage on shares of Hims & Hers Health in a research report on Friday, September 11th. They set a "neutral" rating and a $32.00 price objective for the company. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a report on Monday, July 13th. Finally, Morgan Stanley upped their price target on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $32.43.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia appointed chief medical officers in the United Kingdom and Australia, strengthening local clinical leadership as the company expands internationally. Hims & Hers Names Chief Medical Officers in the UK and Australia
• Neutral Sentiment: Multiple law firms, including Rosen, Kaplan Fox, SBS and Robbins Geller, reminded investors that purchasers of HIMS securities between August 4, 2025, and July 29, 2026, may seek appointment as lead plaintiff by November 2, 2026. These announcements are largely procedural and do not represent new claims by themselves. Rosen Securities Class Action Deadline Notice
• Negative Sentiment: Hims & Hers is the subject of a securities class action alleging that the company and certain executives made material misstatements or omissions, including regarding allegedly deceptive and unlawful privacy practices. The case reportedly follows an FTC complaint alleging serious business misconduct. The allegations have not been proven, but the litigation could create legal costs, potential damages and additional regulatory or reputational pressure. Hims & Hers Securities Class Action Following FTC Complaint
• Negative Sentiment: Recent reports noted that HIMS declined during a session in which the overall market rose, suggesting investor sentiment remains pressured by the FTC-related controversy and lawsuit headlines. Continued coverage from numerous plaintiff firms may keep volatility elevated while investors await developments in the case. HIMS Stock Slides as Market Rises

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.